Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

736 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sunitinib rechallenge in advanced renal cell carcinoma: outcomes of a multicenter retrospective study.
Munárriz J, Reynés G, Sánchez-Lorenzo L, Esteban E, Basterretxea L, de Avila-Lizárraga L, Climent MA, Juan-Fita MJ, Escoín C, Puente J, Cassinello J, Vázquez S, Chirivella I. Munárriz J, et al. Among authors: vazquez s. Cancer Chemother Pharmacol. 2019 Oct;84(4):781-789. doi: 10.1007/s00280-019-03913-3. Epub 2019 Jul 31. Cancer Chemother Pharmacol. 2019. PMID: 31367791
SNPs associated with activity and toxicity of cabazitaxel in patients with advanced urothelial cell carcinoma.
Duran I, Hagen C, Arranz JÁ, Apellaniz-Ruiz M, Pérez-Valderrama B, Sala N, Lainez N, García-Del Muro X, Noguerón E, Climent MÁ, Maroto P, Font A, García-Donas J, Gallardo E, López-Criado P, González Del Alba A, Sáez MI, Vázquez S, Luque R, Rodríguez-Antona C. Duran I, et al. Among authors: vazquez s. Pharmacogenomics. 2016 Apr;17(5):463-71. doi: 10.2217/pgs.15.186. Epub 2016 Mar 29. Pharmacogenomics. 2016. PMID: 27020167 Clinical Trial.
Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma.
Puente J, Laínez N, Dueñas M, Méndez-Vidal MJ, Esteban E, Castellano D, Martinez-Fernández M, Basterretxea L, Juan-Fita MJ, Antón L, León L, Lambea J, Pérez-Valderrama B, Vázquez S, Suarez C, Del Muro XG, Gallardo E, Maroto JP, Samaniego ML, Suárez-Paniagua B, Sanz J, Paramio JM; SOGUG (Spanish Oncology Genitourinary Group). Puente J, et al. Among authors: vazquez s. Oncotarget. 2017 May 2;8(18):30410-30421. doi: 10.18632/oncotarget.16494. Oncotarget. 2017. PMID: 28423742 Free PMC article.
Consensus Recommendations from the Spanish Germ Cell Cancer Group on the Use of High-dose Chemotherapy in Germ Cell Cancer.
González-Billalabeitia E, Sepúlveda JM, Maroto P, Aparicio J, Arranz JA, Esteban E, Gironés R, López-Brea M, Mendez-Vidal MJ, Pinto A, Sastre J, de Prado DS, Terrasa J, Vázquez S, Powles T, Beyer J, Castellano D, Del Muro XG; Spanish Germ Cell Cancer Group and the Spanish Oncology Genitourinary Group. González-Billalabeitia E, et al. Among authors: vazquez s. Eur Urol Focus. 2017 Apr;3(2-3):280-286. doi: 10.1016/j.euf.2016.07.002. Epub 2016 Jul 18. Eur Urol Focus. 2017. PMID: 28753776 Review.
PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer.
Castro E, Romero-Laorden N, Del Pozo A, Lozano R, Medina A, Puente J, Piulats JM, Lorente D, Saez MI, Morales-Barrera R, Gonzalez-Billalabeitia E, Cendón Y, García-Carbonero I, Borrega P, Mendez Vidal MJ, Montesa A, Nombela P, Fernández-Parra E, Gonzalez Del Alba A, Villa-Guzmán JC, Ibáñez K, Rodriguez-Vida A, Magraner-Pardo L, Perez-Valderrama B, Vallespín E, Gallardo E, Vazquez S, Pritchard CC, Lapunzina P, Olmos D. Castro E, et al. Among authors: vazquez s. J Clin Oncol. 2019 Feb 20;37(6):490-503. doi: 10.1200/JCO.18.00358. Epub 2019 Jan 9. J Clin Oncol. 2019. PMID: 30625039
The Challenge of Managing Bladder Cancer and Upper Tract Urothelial Carcinoma: A Review with Treatment Recommendations from the Spanish Oncology Genitourinary Group (SOGUG).
Font A, Luque R, Villa JC, Domenech M, Vázquez S, Gallardo E, Virizuela JA, Beato C, Morales-Barrera R, Gelabert A, Maciá S, Puente J, Rubio G, Maldonado X, Perez-Valderrama B, Pinto A, Fernández Calvo O, Grande E, Garde-Noguera J, Fernández-Parra E, Arranz JÁ. Font A, et al. Among authors: vazquez s. Target Oncol. 2019 Feb;14(1):15-32. doi: 10.1007/s11523-019-00619-7. Target Oncol. 2019. PMID: 30694442 Review.
Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study).
Schmidinger M, Bamias A, Procopio G, Hawkins R, Sanchez AR, Vázquez S, Srihari N, Kalofonos H, Bono P, Pisal CB, Hirschberg Y, Dezzani L, Ahmad Q, Jonasch E; PRINCIPAL Study Group. Schmidinger M, et al. Among authors: vazquez s. Oncologist. 2019 Apr;24(4):491-497. doi: 10.1634/theoncologist.2018-0787. Epub 2019 Mar 13. Oncologist. 2019. PMID: 30867244 Free PMC article.
Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: results from a prospective observational study (CAPRO).
Puente J, González-Del-Alba A, Sala-Gonzalez N, Méndez-Vidal MJ, Pinto A, Rodríguez Á, Cuevas Sanz JM, Muñoz Del Toro JR, Useros Rodríguez E, García García-Porrero Á, Vázquez S. Puente J, et al. Among authors: vazquez s. BMC Cancer. 2019 Aug 5;19(1):766. doi: 10.1186/s12885-019-5974-9. BMC Cancer. 2019. PMID: 31382926 Free PMC article.
736 results